BiotechTube
Home/Pipeline/AMDS Hybrid Prosthesis

AMDS Hybrid Prosthesis

Acute DeBakey Type I Aortic Dissection with Malperfusion

Pivotal (HDE Approved)HDE Approved (Dec 2024); PMA submission targetedPERSEVERE IDE

Key Facts

Indication
Acute DeBakey Type I Aortic Dissection with Malperfusion
Phase
Pivotal (HDE Approved)
Status
HDE Approved (Dec 2024); PMA submission targeted
Company
Artivion, Artivion

About Artivion

Artivion (NYSE: AORT) is a specialized medical device innovator with a mission to deliver breakthrough technologies for aortic disease. The company has built a synergistic portfolio through strategic acquisitions like On-X and Ascyrus Medical, achieving significant milestones including recent FDA HDE approval for its flagship AMDS device. Its strategy centers on dominating the high-complexity aortic surgery market with a combination of biological tissues, advanced prosthetics, and novel hybrid stent-graft systems.

View full company profile

About Artivion

Artivion (NYSE: AORT) is a specialized medical device innovator with a mission to deliver breakthrough technologies for aortic disease. The company has built a synergistic portfolio through strategic acquisitions like On-X and Ascyrus Medical, achieving significant milestones including recent FDA HDE approval for its flagship AMDS device. Its strategy centers on dominating the high-complexity aortic surgery market with a combination of biological tissues, advanced prosthetics, and novel hybrid stent-graft systems.

View full company profile

Therapeutic Areas

Aortic DiseaseCardiac SurgeryVascular Surgery